Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219173 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
A Phase 2 study of Asthma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 531
- Enrollment target
- 20
- Study locations
NCT07219173: Recruiting Phase 2 study of Asthma, sponsored by Eli Lilly and Company.
NCT07219173 is a Phase 2 study of Asthma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 531 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219173, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 531 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Primary Outcome
To assess the asthma exacerbation rate.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brenipatide
Study Locations (20)
Florida
- AMR Clinical - Doral
- Renstar Medical Research - Ocala
- Avanza Medical Research Center - Pensacola
- USF Health - Tampa
California
- NewportNativeMD, Inc. - Newport Beach
- California Medical Research Associates - Northridge
- Peninsula Research Associates - Rolling Hills Estates
Other
- Consultorios Médicos, Organización del Buen Ayre S.R.L. - Buenos Aires
- Centro de Investigaciones Metabólicas (CINME) - Buenos Aires
- Fundación Respirar - Buenos Aires
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
- Allergy and Clinical Immunology Associates - Pittsburgh
Arizona
- AMR Clinical - Tempe
Colorado
- Asthma & Allergy Associates - Colorado Springs - Colorado Springs
Illinois
- Axis Clinical Trials - Westchester - Westchester
Kentucky
- Allergy & Asthma Specialists, P.S.C. - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 531 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT07219173 shows while recruiting
NCT07219173 is an interventional study that assigns participants to a tested intervention. The registered 531 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219173 names 20 study sites across 12 states, led by Florida, California, Other.
Frequently Asked Questions
What is clinical trial NCT07219173 about?
NCT07219173 is a clinical study titled "A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma". The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
What is the current status of trial NCT07219173?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 531 participants. The study started on 2025-10-22. Estimated completion is 2028-06.
What conditions does trial NCT07219173 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07219173?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07219173?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219173 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219173's enrollment target sits among peer trials
531 78th of 374 higher than 297 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
-
Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI